AI & DIGITAL ONCOLOGY
Status and trends in digital pathology
Pathology is going digital. More than 50 AIs cleared for diagnostic use are now available. This article summarises the status quo and gives an outlook of upcoming emerging technologies.
Personalising cancer treatment with AI and digital pathology
Leveraging artificial intelligence and digital pathology, oncology is entering a transformative stage where advanced image analysis and AI-driven biomarkers enable personalised cancer treatment decisions.
Study presents an AI-guided approach to target cancer antigens
The innovative approach was successfully tested on NY-ESO-1 and promises to bypass some current challenges in the identification of T cell receptors for therapeutic use
LATEST NEWS
Findings support de-escalated radiotherapy after surgery in HPV-associated oropharyngeal squamous cell carcinoma
In a phase III trial, lower doses of adjuvant radiotherapy plus docetaxel were associated with reduced toxicity and need for percutaneous endoscopic gastrostomy, with an impact on quality of life
Immune interception represents an exciting opportunity to stop cancer in its tracks
Data from two studies suggest a good rationale for targeting T-cell dysfunction with precision immunotherapy to intercept pre-cancerous lesions
Epigenetic information could harbour biomarkers of diagnosis and prognosis
Presented studies explore different approaches to predict cancer cachexia and inform on the intra-tumour heterogeneity to personalise treatment
OPINIONS
Integrating multiomic spatial profiling and ctDNA for a deeper understanding of cancer complexity
Umberto Malapelle
Next-generation CAR-T cells are in the pipeline
Philippe Cassier
Target-led treatments for lung cancer – are they moving to the next level?
Tony SK Mok
Technology integration and access to eligible patients underpin the growth of early-phase trials in Asia Pacific
Lilian L. Siu
ctDNA and RNA-based tests are expanding colorectal cancer screening options
Frank A. Sinicrope
OPINIONS
Integrating multiomic spatial profiling and ctDNA for a deeper understanding of cancer complexity
Umberto Malapelle
Next-generation CAR-T cells are in the pipeline
Philippe Cassier
Target-led treatments for lung cancer – are they moving to the next level?
Tony SK Mok
Technology integration and access to eligible patients underpin the growth of early-phase trials in Asia Pacific
Lilian L. Siu
ctDNA and RNA-based tests are expanding colorectal cancer screening options
Frank A. Sinicrope